利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

67 条记录 (耗时 0.035 秒)

    Porous biodegradable polymeric materials for cell transplantation
    4.
    发明授权
    Porous biodegradable polymeric materials for cell transplantation 失效
    用于细胞移植的多孔可生物降解聚合物材料

    公开(公告)号：US07462471B2

    公开(公告)日：2008-12-09

    申请号：US10775768

    申请日：2004-02-10

    申请人： Antonios G. Mikos ,  Joseph P. Vacanti ,  Robert S. Langer ,  Linda G. Griffith ,  Georgios Sarakinos

    发明人： Antonios G. Mikos ,  Joseph P. Vacanti ,  Robert S. Langer ,  Linda G. Griffith ,  Georgios Sarakinos

    IPC分类号： C12N11/08 ,  C12N11/04 ,  C12N5/00 ,  C12N5/06 ,  C12N5/08 ,  A61F2/00

    CPC分类号： G02B27/0031 ,  A61L27/18 ,  A61L27/56 ,  A61L2400/06 ,  G03F7/40 ,  H01L21/0273 ,  H01L21/32139 ,  C08L67/04

    摘要： Polymeric materials are used to make a pliable, non-toxic, injectable porous template for vascular ingrowth. The pore size, usually between approximately 100 and 300 microns, allows vascular and connective tissue ingrowth throughout approximately 10 to 90% of the matrix following implantation, and the injection of cells uniformly throughout the implanted matrix without damage to the cells or patient. The introduced cells attach to the connective tissue within the matrix and are fed by the blood vessels. The preferred material for forming the matrix or support structure is a biocompatible synthetic polymer which degrades in a controlled manner by hydrolysis into harmless metabolites, for example, polyglycolic acid, polylactic acid, polyorthoester, polyanhydride, or copolymers thereof. The rate of tissue ingrowth increases as the porosity and/or the pore size of the implanted devices increases. The time required for the tissue to fill the device depends on the polymer crystallinity and is less for amorphous polymers versus semicrystalline polymers. The vascularity of the advancing tissue is consistent with time and independent of the biomaterial composition and morphology.

    摘要翻译： 聚合材料用于制造一种柔韧，无毒，可注射的多孔模板，用于血管向内生长。 通常在约100和300微米之间的孔径允许血管和结缔组织在植入后约10至90％的基质向内生长，并且在整个植入的基质中均匀注射细胞而不损伤细胞或患者。 引入的细胞附着到基质内的结缔组织，并由血管进食。 用于形成基质或支撑结构的优选材料是生物相容的合成聚合物，其通过水解以受控的方式降解成无害的代谢物，例如聚乙醇酸，聚乳酸，聚原酸酯，聚酐或其共聚物。 随着植入装置的孔隙率和/或孔径增加，组织向内生长的速率增加。 组织填充装置所需的时间取决于聚合物的结晶度，对于无定形聚合物与半结晶聚合物相比较少。 前进组织的血管分布与时间一致，与生物材料组成和形态无关。

    Implantation of cell-matrix structure adjacent mesentery, omentum or peritoneum tissue
    7.
    发明授权
    Implantation of cell-matrix structure adjacent mesentery, omentum or peritoneum tissue 失效
    植入细胞基质结构邻近肠系膜，网膜或腹膜组织

    公开(公告)号：US5804178A

    公开(公告)日：1998-09-08

    申请号：US203509

    申请日：1994-02-28

    申请人： Joseph P. Vacanti ,  Robert S. Langer ,  Lynt Johnson

    发明人： Joseph P. Vacanti ,  Robert S. Langer ,  Lynt Johnson

    IPC分类号： A61L27/36 ,  A61L27/38 ,  C12N5/00 ,  C12N11/08 ,  A61F2/18 ,  A61F2/28

    CPC分类号： A61L27/3839 ,  A61L27/3843 ,  A61L27/3869 ,  C12N5/0068 ,  A61L2430/06 ,  C12N2501/18 ,  C12N2533/30 ,  C12N2533/40

    摘要： A matrix structure containing attached cells such as endocrine cells, fibroblasts, endothelial cells or genitourinary cells is implanted in a patient adjacent tissue having a high surface area and vasculature such as mesentery, omentum or peritoneum tissue. Large volumes of cells can be attached to the matrix and the matrix implanted with minimum trauma and blood loss into a patient to produce a functional organ equivalent. Multiple matrix structures containing cells can be implanted to functionally resemble naturally occurring organs. Implanting multiple matrices between folds of the mesentery is particularly well suited for growth of endocrine structures, including liver, pancreas, and adrenal gland. The matrix structure is preferably formed from a biodegradable artificial polymer. Collagen and non-biodegradable materials can also be used, and the matrix structure can be overlaid with a material that enhances cell attachment. Materials such as angiogenesis factors can be incorporated into a matrix and implanted prior to implanting the matrix containing cells or the materials can be incorporated into the matrix containing cells. Cells attached to the matrix may be cultured in vitro prior to implanting. Matrix structures containing different types of cells can be implanted juxtapositioned with each other.

    摘要翻译： 将包含附着细胞如内分泌细胞，成纤维细胞，内皮细胞或泌尿生殖细胞的基质结构植入具有高表面积和脉管系统如肠系膜，网膜或腹膜组织的邻近组织中。 大量的细胞可以连接到基质上，并且基质以最小的创伤和失血植入患者体内以产生功能性器官当量。 可以将包含细胞的多个基质结构植入功能上类似天然存在的器官。 在肠系膜的折叠之间植入多个基质特别适用于内分泌结构的生长，包括肝，胰腺和肾上腺。 基质结构优选由生物可降解的人造聚合物形成。 还可以使用胶原蛋白和不可生物降解的材料，并且可以用增强细胞附着的材料覆盖基质结构。 诸如血管生成因子的材料可以掺入基质中并在植入包含细胞的基质之前植入，或者该材料可以并入含有基质的细胞中。 附着于基质的细胞可以在植入前在体外培养。 含有不同类型细胞的基质结构可以彼此并置。

    Breast tissue engineering
    9.
    发明授权
    Breast tissue engineering 失效
    乳腺组织工程

    公开(公告)号：US5716404A

    公开(公告)日：1998-02-10

    申请号：US358189

    申请日：1994-12-16

    申请人： Joseph P. Vacanti ,  Anthony Atala ,  David J. Mooney ,  Robert S. Langer

    发明人： Joseph P. Vacanti ,  Anthony Atala ,  David J. Mooney ,  Robert S. Langer

    IPC分类号： C12N5/06 ,  A61L27/00 ,  A61L27/38 ,  C12N5/08 ,  A61F2/12

    CPC分类号： A61L27/3804 ,  A61F2/12 ,  A61L27/3839 ,  A61F2002/0086 ,  A61F2250/0003 ,  A61L2430/04

    摘要： Methods and compositions are described herein for reconstruction or augmentation of breast tissue. Dissociated cells, preferably muscle cells, are implanted in combination with a suitable biodegradable, polymeric matrix to form new tissue. There are two forms of matrices which can be used: a polymeric hydrogel formed of a material such as alginate having cells suspended therein, and a fibrous matrix having an interstitial spacing between about 100 and 300 microns. Preferred polymeric materials are those degrading over about one to two months, such as polylactic acid-glycolic acid copolymers. The matrices can be seeded prior to implantation or implanted, allowed to vascularize, then seeded with cells. In a preferred embodiment, the cell-matrix structures are implanted in combination with tissue expander devices. As cell-matrix is implanted, or cells proliferate and form new tissue, the expander size is decreased, until it can be removed and the desired reconstruction or augmentation is obtained. The preferred cell types are muscle cells, although other types of mesenchymal cells, fibroblasts, chondrocytes, and adipocytes can be used. Cells obtained from tissue such as the labia can be used for specialized applications such as formation of a nipple type tissue. Other materials, such as bioactive molecules that enhance vascularization of the implanted tissue and/or which inhibit ingrowth of fibrotic tissue, can be implanted with the matrix to enhance development of more normal tissue.

    摘要翻译： 本文描述了用于重建或增加乳腺组织的方法和组合物。 离解的细胞，优选肌肉细胞，与合适的可生物降解的聚合物基质组合植入以形成新的组织。 可以使用两种形式的基质：由具有悬浮于其中的细胞的诸如藻酸盐的材料形成的聚合物水凝胶和具有约100至300微米间隙的纤维基质。 优选的聚合物材料是在约一至两个月内降解的物质，例如聚乳酸 - 乙醇酸共聚物。 可以在植入或植入之前将基质接种，允许血管化，然后用细胞接种。 在优选实施例中，细胞 - 基质结构与组织扩张器装置组合植入。 随着细胞基质被植入，或细胞增殖并形成新的组织，扩张器尺寸减小，直到其被去除并且获得所需的重建或增加。 优选的细胞类型是肌肉细胞，尽管可以使用其他类型的间充质细胞，成纤维细胞，软骨细胞和脂肪细胞。 从组织如阴唇获得的细胞可用于特殊应用，例如形成乳头型组织。 其他材料，例如增强植入组织的血管形成和/或抑制纤维化组织向内生长的生物活性分子可以用基质植入以增强更正常组织的发育。